<DOC>
	<DOCNO>NCT00416546</DOCNO>
	<brief_summary>This study assess safety effect multiple dos AEB071 healthy volunteer compare ethnicity , metabolic , safety effect Caucasian Japanese healthy subject receive single multiple dos AEB071 .</brief_summary>
	<brief_title>Safety AEB071 Healthy Volunteers Compare Ethnicity , Metabolic , Safety Effects Between Caucasian Japanese Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy , male female subject provide write , inform , consent enter study . Light smoker ( â‰¤10 cigarettes/day ) eligible inclusion study . Smokers define subject report cigarette use urine cotinine great 500 ng/mL . Female subject must either surgically sterilize least 6 month practice acceptable form birth control ( i.e . double barrier method intrauterine device plus condom , spermicidal gel plus condom ) . Subjects must body weight 45 90 kg body mass index ( BMI ) 1828 kg/m2 . Japanese subject 1st , 2nd , 3rd generation ethnic origin Caucasian . Japanese subject define Japanese ethnicity 4 grandparent Japanese descent . Generations define follow : 'First generation ' Japanese subject bear Japan parent Japanese ethnicity . 'Second generation ' define subject bear outside Japan 1st generation Japanese parent . 'Third generation ' define subject bear outside Japan 2nd generation Japanese parent , i.e . 4 grandparent Japan parent subject bear elsewhere . Caucasians define subject four grandparent European descent . Presence and/or history clinically significant illness within two week prior dose , history drug alcohol abuse within 12 month prior dose , use prescription drug overthecounter ( OTC ) medication ( acetaminophen acceptable ) within 14 day prior dose . Presence clinically significant systemic illness , active infectious process ( viral bacterial ) , e.g. , cold sore , document drug allergy may deteriorate affect subject 's safety ability cooperate study . Laboratory clinical evidence suggestive liver renal disease , history heart disease , history autonomic dysfunction ( e.g . history fainting , orthostatic hypotension , sinus arrhythmia ) , history acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) , history major gastrointestinal disease , history clinical evidence pancreatic injury pancreatitis Subjects rest heart rate &lt; 50 beat per minute ( bpm ) Subjects systolic blood pressure &lt; 90 diastolic blood pressure &lt; 50 . Subjects lymphocyte count less 1200/mm3 total white blood cell ( WBC ) great 10000/mm3 baseline A past medical history clinically significant electrocardiogram ( ECG ) abnormalities family history prolong QTinterval syndrome . Subjects intend receive live attenuate vaccine 4 week prior study period . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Healthy Caucasians</keyword>
	<keyword>Healthy Japanese subject</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>early T-cell activation blocker</keyword>
	<keyword>inhibition protein kinase C</keyword>
</DOC>